Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company IOptima Ltd. has obtained EU CE Mark certification for its OT-134 non-invasive laser glaucoma treatment.
In contrast to US Food and Drug Administration (FDA) approval, CE Mark certification only relates to a product's safety, but not necessarily to its efficiency. Product safety certification is critical for IOptima, given the scary nature of its therapy - laser beams that reduce the internal eye pressure, even though it does not penetrate the eye membrane. The company will soon begin marketing the OT-134 in Europe.
Lire l'intégralité de l'article » (Source: Globes)
Enfin un traitement chirurgical du glaucome à la fois sûr et simple